louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06598228: Acute Kidney Injury and Recovery Mode in Pediatric Liver Transplantation
Official title: Acute Kidney Injury and Recovery Mode in Pediatric Liver Transplantation
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Postoperative Acute Kidney Injury
Pediatric Liver Transplantation
Lead sponsor: Tianjin First Central Hospital
Sponsor class: OTHER
First posted: 2024-09-19
Enrollment: 700
Sex: ALL
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This study was conducted on pediatric patients (aged ≤18 years) who received liver transplantation at Tianjin First Central Hospital in China between January 1, 2014 and December 31, 2018

Brief summary: Acute kidney injury (AKI) is a common complication after pediatric liver transplantation (PLT), and renal impairment after LT has proven to be related with increased graft failure and mortality. The recovery mode of kidney injury after PLT has not been systematically studied. Therefore, in this study the investigators aimed to systematically evaluate prognosis of AKI after PLT, combine the recovery mode of AKI with related risk factors, and establish a relationship between AKI and CKD.


Eligibility criteria: Inclusion Criteria:

* Patients who received a liver transplant for the first time.
* Patients who were younger than 18 years of age at the time of transplant.

Exclusion Criteria:

* Patients with incomplete clinical data.
* Patients with less than 5 years of follow-up.
* Patients who have combined multiple solid organ transplants.
* Patients with preoperative renal impairment (eGFR\<60ml/min/1.73 m2 or prior renal replacement therapy).

Primary outcomes:
measure: Graft survival
timeFrame: Based on the most recent follow-up before December 31, 2023. The investigators collected clinical data of patients from 2014 to 2018, and followed enrolled participants until at least 5 years after surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Tianjin
country: China
facility: Tianjin First Central Hospital
Study officials:
References:
Clinical trial NCT05380128: Association Study Between VDR Gene Polymorphisms and Risk and Features of MG in Han Chinese Population
Official title: Association Study Between Vitamin D Receptor Gene Polymorphisms and Risk and Features of Myasthenia Gravis in Han Chinese Population
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Myasthenia Gravis, Ocular
Gene Polymorphism
Lead sponsor: Beijing Tongren Hospital
Sponsor class: OTHER
First posted: 2022-05-18
Enrollment: 297
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with confirmed myasthenia gravis and healthy volunteers.

Brief summary: The Vitamin D receptor gene (VDR) polymorphisms are the candidate genetic variants for susceptibility to autoimmune diseases. In the present study, the investigators aimed to assess the association between VDR polymorphisms and myasthenia gravis (MG) susceptibility and disease features in Chinese Han population.The patients with MG and healthy controls were genotyped for VDR rs1544410, rs2228570, rs731236, and rs7975232 polymorphisms using the improved multiple ligase detection reaction. Information on age at onset, acetylcholine receptor antibody (AChR-Ab) and muscle-specific kinase antibody (MuSK-Ab) status, thymus status, involved muscles at onset and Osserman type at the maximum worsening during 2 years follow-up were obtained and used as the grouping basis of sub-classifications. Intergroup comparisons of allele and genotype frequencies, haplotype distributions were performed between MG group and the control group, and between each pair of MG subgroups.


Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of myasthenia gravis.
* Han Chinese population.
* Must be able to complete a 2-year follow-up visit.

Exclusion Criteria:

* Clinical data collection can not be completed.
* Poor compliance.

Primary outcomes:
measure: Association between VDR gene polymorphism and MG susceptibility
timeFrame: up to 2 years
Secondary outcomes:
measure: Association of VDR gene polymorphism with MG subgroups
timeFrame: up to 2 years
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Tongren Hospital
Study officials:
References:
Clinical trial NCT01445028: Isotretinoin for Proliferative Vitreoretinopathy
Official title: Determining the Effect of Low-dose Isotretinoin on Proliferative Vitreoretinopathy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Proliferative Vitreoretinopathy
Lead sponsor: Wills Eye
Sponsor class: OTHER
First posted: 2011-10-03
Enrollment: 109
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Proliferative vitreoretinopathy (PVR), or secondary scarring on and around the retina, is an important cause of retinal re-detachment. The purpose of this study is to evaluate the effect of oral isotretinoin, which inhibits the growth of cells responsible for proliferative vitreoretinopathy (PVR), on recurrent retinal detachment.

Detailed description: Small retrospective studies have shown isotretinoin to be effective in reducing the rate of recurrent retinal detachment in patients with or at high risk for developing PVR. This is a prospective study to evaluate a low dose of oral isotretinoin in this regard. There are two arms to the study: 1) eyes with recurrent retinal detachment due to existing PVR, and 2) eyes with primary detachment and features associated with a high risk of PVR formation. Eligible and willing patients will receive a 12-week course of isotretinoin, and will be followed for retinal attachment rate, and PVR and/or ERM (epiretinal membrane) formation.

Eligibility criteria: Inclusion Criteria:

* 18-70 year-old men or 50-70 year-old, post-menopausal women.
* Healthy enough to participate in the study.
* Willing and able to consent to participation.
* Recurrent PVR-associated RD occurring at least 2 weeks after RD repair or
* Primary RD (retinal detachment) associated with one or more high-risk features

Exclusion Criteria:

* History of hypersensitivity to isotretinoin.
* Current use of a corticosteroid (excluding topical).
* Any history of depression, anorexia, liver or pancreatic disease.
* More than one prior surgical RD repair.
* Patients with closed funnel retinal detachments.
* Patients with chronic retinal detachment, defined as longer than 12 weeks.
* Any use an oral retinoid within 6 months.
* Systemic chemotherapy within 6 months.
* Patients taking supplemental vitamin A.
* Corneal opacity sufficient to impair surgical view.
* Proliferative diabetic retinopathy.

Primary outcomes:
measure: Rate of Retinal Attachment
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Wills Eye Institute
state: Pennsylvania
Study officials:
affiliation: Wills Eye Institute
name: Richard S Kaiser, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03978728: Analysis of Endotoxin Activity in Patients With ECMO
Official title: Analysis of Endotoxin Activity in Patients With Extracorporeal Membrane Oxygenation Life Support System
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cardiovascular Shock
Respiratory Failure
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2019-06-07
Enrollment: 55
Sex: ALL
Minimum age (years): 20
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Paitents with extra-corporeal membrane oxygenation support

Brief summary: Extra-corporeal membrane oxygenation (ECMO) can temporarily help patients gain time to wait for cardiopulmonary recovery or further treatment in patients with cardiopulmonary failure. Whether the blood flow provided by the ECMO can maintain the perfusion of various organs is an important factor affecting survival. Some ECMO patients died after the complication of sepsis. Our previous pilot analysis has recognized several ECMO patients with complicated sepsis has high endotoxin activity level. Endotoxemia can also occur in heart surgery and after cardiopulmonary bypass, trauma, organ transplantation, and out-of-hospital cardiac arrest patients. These trials used endotoxin activity analysis (EAA, EAATM, Spectral Diagnostics Inc., Canada) to analyze endotoxin activity. In addition, studies have indicated that the combination of procalcitonin (PCT) concentration and EAA activity can improve the accuracy of predicting sepsis. The primary aim of this study is to detect endotoxin activity in patients with ECMO support and compare whether the prognosis was associated with different level of EAA activity. The secondary aims are to analyze the risk factors leading to high EAA activity and investigate the diagnostic value of septic shock combining PCT examination. We suggest that the results of this study may help the ECMO medical team identify patients at high risk for septic shock and conduct adequate managements to improve patient survival and quality of life after survival.


Eligibility criteria: Inclusion Criteria:

* patients with ECMO support

Exclusion Criteria:

* \< 20 years old or \> 90 years old
* not be able to collect blood sample within 48 hours after placement of ECMO
* change plan to palliative care and plan to remove ECMO
* non-native speakers

Primary outcomes:
measure: Endotoxin activity level
timeFrame: within 48 hours
Secondary outcomes:
measure: Endotoxin activity level
timeFrame: within 24 hours
measure: Endotoxin activity level
timeFrame: within 72 hours
measure: Endotoxin activity level
timeFrame: within 96 hours
measure: Procalcitonin level
timeFrame: within 48 hours
measure: Cystatin C level
timeFrame: within 48 hours
measure: Diamine oxidase level
timeFrame: within 48 hours
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: National Taiwan University Hospital
name: Yu-Chang Yeh, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04149028: Platelet Rich Plasma Injection Into Ovary of Patients With Premature Ovarian Insufficiency
Official title: Platelet Rich Plasma Injection Into Ovary of Patients With Premature Ovarian Insufficiency
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Premature Ovarian Failure
Keywords: Premature ovarian insuffiency
Infertility
PRP
Lead sponsor: Tanta University
Sponsor class: OTHER
First posted: 2019-11-04
Enrollment: 16
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: All eligible patient will recieve the treatment with PRP
Primary purpose: TREATMENT

Brief summary: All encountered cases with POI will be assessed and examined then investigated. Eligible cases will be included in the study

Detailed description: Patients will be subjected to injection of autologous PRP inside the ovary about 0.5-1 mml by laparoscopy

Eligibility criteria: Inclusion Criteria:

* Premature ovarian insufficiency diagnosed by:
* FSH\> 40 Amenorrhea Menopuasal symptoms Infertility

Exclusion Criteria:

* Refusal to participate Secondary POI due chemotherapy, surgery, or radiotherapy Previous treatment with PRP

Primary outcomes:
measure: Resumption of ovarian hormonal function
timeFrame: 3-6 months
measure: Resumption of ovarian folliclugenesis
timeFrame: 3-6 months
Secondary outcomes:
measure: Resumption of menstruation
timeFrame: 3-6 months
measure: Fertility potential
timeFrame: 3-6 months
Other outcomes:
Locations:
city: Tanta
country: Egypt
facility: Adel Elgergawy
Study officials:
References:
Clinical trial NCT06520293: Effects of a Single Oral Dose of Sweet Protein Sweelin® on Blood Glucose and Insulin Levels in Healthy Adults
Official title: Effects of a Single Oral Dose of Sweet Protein Sweelin® on Blood Glucose and Insulin Levels in Healthy Adults: a Crossover, Double Blinded Clinical Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Healthy Adults
Lead sponsor: Amai Proteins
Sponsor class: INDUSTRY
First posted: 2024-07-25
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: The study aims to evaluate, for the first time, the post-prandial effects of a single oral administration of Serendipity Berry Sweet Protein sweelin® compared to glucose and stevia, as a commercial sweetener, in healthy adults. The study design is a single center, randomized, crossover study.

Each subject will receive a single oral dose of sweelin® compared with an equivalently sweet dose of glucose and stevia dissolved in a water beverage with flavor.

The advantage of a crossover design is that it will allow to compare the blood glucose and insulin levels of each subject to his baseline in every test beverage, and to remove the inter-subject variability. The post-prandial effects will be monitored with multiple blood sampling up to 120 minutes post dosing.


Eligibility criteria: Inclusion Criteria:

1. Healthy subjects
2. Age 18-70 years
3. BMI between 18.0 and 33.0 calculated as Weight (Kg)/Height (m2).
4. Stable weight in the last 3 months (+/-5kg).
5. Subjects must be able to adhere to the visit schedule and protocol requirements and be available to complete the study.

Exclusion Criteria:

1. Pregnant or breastfeeding women.
2. Subjects with a significant allergic response or history of food allergies deemed clinically significant or exclusionary for the study.
3. Diabetes mellitus or use of medications affecting glucose metabolism.
4. Subjects with any gastrointestinal disease which may affect absorption
5. Subjects with any acute medical situation (e.g. acute infection) within 48 hours of study start, which is considered of significance by the Principal Investigator.
6. Subjects which have undergone major surgery in the last 3 months.
7. Subjects who are non-cooperative or unwilling to sign the consent form.

Primary outcomes:
measure: Blood glucose incremental area under the curve (iAUC)
timeFrame: 120 minutes after single oral dose administration
Secondary outcomes:
measure: Insulin incremental area under the curve (iAUC)
timeFrame: 120 minutes after single oral dose administration
Other outcomes:
Locations:
Study officials:
affiliation: Tel-Aviv Sourasky Medical Center
name: David Zeltser, Prof.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04804293: Assessment of Carpal Tunnel Syndrome by Shearwave Elastography
Official title: Treatment Monitoring of Carpal Tunnel Syndrome Using Shear Wave Elastography: a Pilot in Vivo Study
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Carpal Tunnel Syndrome
Keywords: Shear Wave Elastography
Peripheral compression neuropathy
Neuropathy
Demyelination
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2021-03-18
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Intervention model description: Central hypothesis is that SWE provides quantitative information about the physical properties of the MN and surrounding tissue that help to identify carpal tunnel syndrome, its severity and response to treatment.
Primary purpose: DIAGNOSTIC

Brief summary: This study is being done to test a new ultrasound method to detect possible stiffness problems within wrist(s). The purpose of this research is to the test the effectiveness of a new ultrasound method to check the nerve and surrounding tissue in both wrist of patient volunteers before and after treatment.

Detailed description: The ultrasound system is FDA approved. The risks associated with this research study are not beyond the normal risk of conventional ultrasound and should not cause you any discomfort. Ultrasound at the intensity levels and duration used in this study has not been shown to present risk to humans. The investigators will conduct the SWE study on the set time point when the patient returns for follow-up after the therapy (surgical decompression or corticosteroid injection).

A set of pictures will be taken of patients wrists by the FDA approved ultrasound system. This system uses a special type of ultrasound for imaging your wrists.

The ultrasound study will be repeated after 3 and 6 months after the treatments.

Eligibility criteria: Inclusion Criteria:

* Male and female volunteers.
* Age ≥ 18 years old.
* Having unilateral symptom of wrist pain
* Scheduled for corticosteroid injection or surgery

Exclusion Criteria:

* Individuals less than 18 years of age.
* Prior surgery.
* People considered in "vulnerable" populations.
* Having bilateral symptoms

Primary outcomes:
measure: Evaluate the treatment response by shear wave elastography (SWE)
timeFrame: First 3 months
Secondary outcomes:
measure: Correlate shear wave elastography (SWE) measurements with patient-reported measures of symptom severity and functional status scores and severity of pre-operative electrodiagnostic tests (EDX) elasticity
timeFrame: 3 to 6 months
Other outcomes:
Locations:
city: Scottsdale
country: United States
facility: Mayo Clinic in Arizona
state: Arizona
city: Rochester
country: United States
facility: Mayo Clinic in Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Azra Alizad, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03241693: Blended-learning in Physiotherapy: Professional Ethics
Official title: Effect of a Blended-learning Programme on Physiotherapy Students´ Attitude, Knowledge and Opinions Towards Learning Professional Ethics.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Ethics
Attitude
Knowledge
Lead sponsor: University of Valencia
Sponsor class: OTHER
First posted: 2017-08-07
Enrollment: 130
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study was to assess the effect of a blended-learning model on physiotherapy students´ attitude, knowledge and opinions towards learning professional ethics.

A simple-blind clinical trial was performed. An eight-month blended learning program to teach professional ethics in clinical practices was worked out. An online syllabus and online activities were elaborated, whilst face to face active participation techniques were performed to discuss ethical issues detected among practices. Students´ attitudes, knowledge and opinions towards learning professional ethics were assessed. Non-parametric tests were carried out. All the participants were informed about the study and procedures, and provided written informed consent.

Detailed description: Participants. 139 third-year degree students of Physiotherapy Degree at the University, aged between 20 and 30 years, were recruited voluntarily from September 2010 to July 2011. All enrolled participants were informed of the purpose of the study and procedures, and provided written informed consent. The study was carried out at the institution where the authors belong.

Research design. A prospective simple-blind trial was performed. After baseline assessment, participants were allocated to one of the two groups (control group, n=65; experimental group, n=64). An external assistant not involved in the study performed assignment.

Intervention. A Physiotherapy professor with over-10-year experience in Ethics and Physiotherapy performed the teaching methodology. She opened the allocation envelopes and applied the teaching methodology to the EG according to the group assignment. The intervention consisted of an eight-month blended-learning program based in professional ethics, including two phases: A) online syllabus and online activities (4 months); and B) face to face group sessions (4 months).

Eligibility criteria: Inclusion Criteria:

* To study the physical therapy degree at the University of Valencia

Exclusion Criteria:

* Exclusion criterion was having prior training on Ethics subject

Primary outcomes:
measure: Attitude towards learning professional ethics
timeFrame: 8 months
Secondary outcomes:
measure: Knowledge towards learning professional ethics
timeFrame: 4 months, 8 months
measure: Opinions about the blended-learning programme.
timeFrame: 4 months, 8 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00767793: A Placebo-Controlled Study of INS117548 Ophthalmic Solution in Subjects With Glaucoma (P08650)
Official title: A Multi-Center, Double-Masked, Randomized, Placebo-Controlled, Ascending Dose Study of INS117548 Ophthalmic Solution in Subjects With Bilateral Ocular Hypertension or Early Primary Open Angle Glaucoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Glaucoma
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2008-10-07
Enrollment: 84
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety and tolerability of INS117548 ophthalmic solution.


Eligibility criteria: Inclusion Criteria:

* Have a diagnosis of bilateral ocular hypertension or early primary open angle glaucoma
* Have best corrected visual acuity in both eyes of at least +0.5 or better

Exclusion Criteria:

* Are diagnosed with closed angle glaucoma, exfoliation syndrome or exfoliation glaucoma, and pigment dispersion or secondary glaucoma
* Have a history of any type of intraocular surgery, except for cataract surgery
* Have had cataract surgery within three months

Primary outcomes:
measure: Incidence of adverse events
timeFrame: 15
measure: Rate of discontinuation
timeFrame: 15
measure: Changes in: >Ophthalmic exam parameters >Corneal thickness >Intraocular pressure >Visual Acuity >Physical exam, vital signs and laboratory parameters
timeFrame: 15
measure: Compliance
timeFrame: 15
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Medical Monitor, Inspire
name: Reza Haque, MD, PhD
role: STUDY_DIRECTOR
References: